MONMOUTH JUNCTION, N.J.,
April 3, 2014 /PRNewswire/
-- CytoSorbents Corporation (OTCQB: CTSO), a critical care
immunotherapy company using blood purification to treat life
threatening conditions in the intensive care unit, announced that
Dr. Phillip Chan, MD, PhD, Chief
Executive Officer of CytoSorbents, will present a corporate
overview at the 13th Annual Needham Healthcare
Conference at the Westin Grand Central Hotel in New York City, New York.
Dr. Chan will present from 10:00 - 10:40
AM EDT on Tuesday, April 8,
2014. The executive management team will also be available
during the day for pre-scheduled one-on-one meetings with
institutional investors. A live and archived audio and slide
webcast of the presentation will be available at
http://www.cytosorbents.com/invest.htm The presentation will
be archived for at least 30 days.
The Company's flagship product, CytoSorb®, is the only
specifically approved extracorporeal cytokine filter in the
European Union. It is clinically proven to reduce excessive blood
levels of cytokines, often called "cytokine storm", which can drive
dangerous and deadly widespread inflammation in critically-ill
patients. This uncontrolled inflammation can rapidly lead to the
damage and failure of vital organs, the cause of nearly half of all
deaths in the intensive care unit (ICU). The goal of CytoSorb®
therapy is to prevent or treat organ failure by reducing severe
inflammation in a diverse set of life threatening conditions such
as sepsis, lung injury, trauma, burn injury, and pancreatitis, as
well as during high risk cardiac surgery. CytoSorb® is
commercially available in multiple European and Asian
countries.
Needham's Healthcare Conference focuses on connecting leading
emerging life science companies and institutional investors.
This year, senior management teams from approximately 120 companies
in the biotechnology, specialty pharmaceutical, medical technology
and diagnostic sectors have been invited and scheduled to present.
About CytoSorbents Corporation
CytoSorbents is a critical care focused immunotherapy company
using blood purification to modulate inflammation -- with the goal
of preventing or treating multiple organ failure in
life-threatening illnesses. Organ failure is the cause of nearly
half of all deaths in the intensive care unit, with little to
improve clinical outcome. CytoSorb®, the Company's flagship
product, is approved in the European Union as a safe and effective
extracorporeal cytokine filter, designed to reduce the "cytokine
storm" that could otherwise cause massive inflammation, organ
failure and death in common critical illnesses such as sepsis, burn
injury, trauma, lung injury, and pancreatitis. These are conditions
where the risk of death is extremely high, yet no effective
treatments exist. CytoSorbents' purification technologies are based
on biocompatible, highly porous polymer beads that can actively
remove toxic substances from blood and other bodily fluids by pore
capture and surface adsorption. CytoSorbents has numerous products
under development based upon this unique blood purification
technology, protected by 32 issued US patents and multiple
applications pending, including HemoDefend™, ContrastSorb,
DrugSorb, and others. Additional information is available for
download on the Company's website: http://www.cytosorbents.com/
Forward-Looking Statements
This press release includes forward-looking statements intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements in this press release are not promises or guarantees and
are subject to risks and uncertainties that could cause our actual
results to differ materially from those anticipated. These
statements are based on management's current expectations and
assumptions and are naturally subject to uncertainty and changes in
circumstances. We caution you not to place undue reliance upon any
such forward-looking statements. Actual results may differ
materially from those expressed or implied by the statements
herein. Risk factors are detailed in the Company's Form 10-K filed
with the SEC on March 31, 2014, which
is available at http://www.sec.gov.
Please Click to Follow us on Facebook and
Twitter
SOURCE CytoSorbents Corporation